| Document |
Document Title |
|
WO/2024/098890A1 |
A pyridone compound and a preparation method therefor, a pharmaceutical composition and a use. The structure of the pyridone compound is as shown in formula (I), and the pyridone compound comprises an isomer, a pharmaceutically acceptabl...
|
|
WO/2024/100212A1 |
The application relates to the crystalline Form 1S of Asciminib hydrochloride and processes for the preparation thereof. Also described are solvates of Asciminib with 2-butanol, isobutanol, tert- butanol, 2-methyl tetra hydrofuran and cy...
|
|
WO/2024/102706A1 |
Provided herein are methods of treating, preventing, managing, and/or ameliorating androgen receptor mediated diseases with a combination of 3-((3- aminophenyl)amino)piperidine-2, 6-dione compounds and a second agent.
|
|
WO/2024/099404A1 |
The present application relates to a nitrogen-containing spirocyclic compound, a pharmaceutical composition and a use thereof. The nitrogen-containing spirocyclic compound has the structural formula represented by formula (I). The compou...
|
|
WO/2024/099996A1 |
The invention relates to a novel compound having the formula 6-[[(3R)-1-Ethyl-3-piperidyl]amino]-3-(4-hydroxyindan-5-yl)-
4-methyl-1,2,4-triazin-5-one or 6-[[(3R)-1-ethyl-3-piperidyl]amino]-3-(2-hydroxy-3-bicyclo[4
.2.0]octa-1,3,5-trieny...
|
|
WO/2024/101764A1 |
The present invention relates to: an isoindolinone derivative compound having a glutarimide mother nucleus in which quinoline is substituted; and application thereof, and, more specifically, to an isoindolinone derivative compound having...
|
|
WO/2024/099435A1 |
The present invention provides a compound represented by formula I, and a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof. As a TEAD inhibitor, the compound can significantly inhibi...
|
|
WO/2024/102927A1 |
The disclosure provides compounds, in part, compounds of Formula I, Formula II or Formula III and their use in treating medical diseases or disorders, such as neurodegenerative diseases, e.g., Parkinson's disease. Pharmaceutical composit...
|
|
WO/2024/101337A1 |
Provided in one embodiment is a compound, or a pharmaceutically acceptable salt thereof, capable of suppressing a splicing abnormality that causes onset or advance of a disease. The present disclosure provides in one embodiment a compoun...
|
|
WO/2024/102956A1 |
Conjugates comprising a fibroblast activation protein alpha (FAPĪ±)-targeted ligand, a bifunctional or trifunctional linker, and an imaging or therapeutic agent; compositions comprising the conjugates; and methods of use in the imaging a...
|
|
WO/2024/099458A1 |
Disclosed in the present invention are a piperidine-substituted benzoic acid compound, and a pharmaceutical composition and the use thereof. The piperidine-substituted benzoic acid compound of the present invention is a compound as shown...
|
|
WO/2024/102683A1 |
There are disclosed compounds of the following formula (I): (Formula (I)) or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 a...
|
|
WO/2024/098210A1 |
The present invention relates to the technical field of drug research and development, and specifically relates to an aryl carboxylic acid compound, in particular to a use of the aryl carboxylic acid compound in the preparation of an Mrg...
|
|
WO/2024/099229A1 |
The present invention relates to a 2-aminopyrimidine compound as represented by general formula (I) and a pharmaceutically acceptable salt, solvate, or prodrug thereof, preparation methods therefor, and a pharmaceutical composition conta...
|
|
WO/2024/101172A1 |
A compound represented by formula (I) or a salt thereof. In formula (I): A1 is a nitrogen atom or a group represented by CH; R1 is a C1-6 haloalkoxy group or a C1-6 haloalkylthio group; Ra is a hydrogen atom or a substituted or unsubstit...
|
|
WO/2024/098692A1 |
A Wee1 protein kinase degrading agent and a use thereof. Specifically, the compound represented by formula I or a pharmaceutically acceptable salt thereof, and a use thereof in the treatment of proliferative diseases. W-L-D (I).
|
|
WO/2024/099993A1 |
The invention relates to novel compounds having the general formula (I) wherein R1, R2, R3, R4a, R4b, and R5 are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2024/099411A1 |
Provided are a crystal form of a free base of compound I, a salt of compound I and a crystal form of the salt of compound (I). The crystal form and the salt form have excellent effects in terms of physical stability, chemical stability, ...
|
|
WO/2024/099416A1 |
The present invention relates to a fused tricyclic PARP1 inhibitor, a preparation method therefor, and a use thereof. In particular, the present invention relates to a compound capable of inhibiting poly ADP-ribose polymerase activity, a...
|
|
WO/2024/099241A1 |
The present invention relates to a deuterated pyrimidine derivative represented by formula I or a pharmaceutically acceptable salt, an isomer, a metabolite, a prodrug, a solvate, or a hydrate thereof. The present invention further relate...
|
|
WO/2024/101336A1 |
One embodiment of the present invention provides a compound, or a pharmaceutically acceptable salt thereof, capable of suppressing the splicing anomalies that are a factor in the onset or progression of disease. This disclosure relates t...
|
|
WO/2024/099398A1 |
Disclosed in the present invention are a class of sulfonamide compounds containing an ortho-fused heterocycle and the use thereof, and specifically disclosed is a compound of formula (II), a stereoisomer or a pharmaceutically acceptable ...
|
|
WO/2024/100599A1 |
The present disclosure encompasses solid state forms of Zavegepant hydrochloride, in embodiments crystalline polymorphs of Zavegepant hydrochloride, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2024/099437A1 |
Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2024/101763A1 |
The present invention relates to an isoindolinone derivative compound having a glutarimide mother nucleus, and an application thereof, and more specifically, to an isoindolinone derivative compound in which a glutarimide mother nucleus i...
|
|
WO/2024/102849A1 |
The present disclosure provides certain bifunctional compounds that cause degradation of Cyclin-dependent kinase 2 (CDK2) via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated by CDK2. Also prov...
|
|
WO/2024/099430A1 |
Provided are a pharmaceutical composition of a compound of formula (I) or a stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutical formulation thereof; and a preparation method for the pharmaceutical composition...
|
|
WO/2024/100115A1 |
A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
|
|
WO/2024/102444A1 |
Provided herein is technology relating to particular heterocyclic compounds, including compounds that comprise structural modifications of arundine and substituted derivatives of arundine, and particularly, but not exclusively, to use of...
|
|
WO/2024/099403A1 |
A thioether compound having a soft drug property and a use thereof, and a pharmaceutical composition and a use thereof. The compound has a structural formula of formula I. A thioether structure in the compound has pharmacological activit...
|
|
WO/2024/102886A1 |
Disclosed are compounds of Formulas (I): (I) or a salt thereof, wherein R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds as inhibitors of TLR9, and pharmaceutical compositions comprising such comp...
|
|
WO/2024/102884A1 |
Disclosed are compounds of Formulas (I): (I) or a salt thereof, wherein L, R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds as inhibitors of TLR9, and pharmaceutical compositions comprising such c...
|
|
WO/2024/099168A1 |
Disclosed is a 2,4,5-trisubstituted pyrimidine compound having a structure as represented by the formula (I) compound, an isotope labeled compound, or an optical isomer, a geometric isomer, a tautomer or an isomer mixture thereof, or a p...
|
|
WO/2024/094170A1 |
Disclosed are an inhibitor compound of ubiquitin-specific protease 1 and a use thereof. The inhibitor compound specifically relates to a compound represented by formula (I) or an enantiomer, a diastereomer, a racemate, a tautomer, a ster...
|
|
WO/2024/097948A1 |
Provided herein are compounds, including compounds of Formula (I) (e.g., compounds of Formula (I-a)), and pharmaceutically acceptable salts, stereoisomers, tautomers, isotopically labeled derivatives, solvates, hydrates, polymorphs, co-c...
|
|
WO/2024/097953A1 |
The present disclosure relates to compounds (I) and compositions for inhibition of RAF serine/threonine protein kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers.
|
|
WO/2024/096117A1 |
Provided are: a carbon dioxide absorbing/releasing liquid that has high carbon dioxide absorbing performance and high carbon dioxide releasing performance at low temperature, and that is less likely to degrade when absorbing and releasin...
|
|
WO/2024/095005A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: wherein V, W, X, Y, Z, A1, A2, A3, A4, A5, A6, A7, A8, A9 and R3 are as defined in the specification,...
|
|
WO/2024/094185A1 |
The present invention belongs to the technical field of medicine, relates to an NLRP3 inflammasome inhibitor and a use thereof, and specifically relates to a compound represented by a general formula (A') or a pharmaceutically acceptable...
|
|
WO/2024/093956A1 |
The present invention relates to the technical field of medicines, in particular to a polycyclic poly(ADP-ribose) polymerase (PARP) selective inhibitor compound as represented by general formula (I), a pharmaceutically acceptable salt th...
|
|
WO/2024/094819A1 |
The present invention provides compounds of Formula (Ia) or (Ib) and methods of use thereof.
|
|
WO/2024/095012A1 |
The invention relates to a compound of formula (Ia) and related aspects.
|
|
WO/2024/097897A1 |
The present disclosure relates to novel compounds which are Liver X Receptor (LXR) modulators and to pharmaceutical compositions containing same. The present disclosure further relates to the use of said compounds in the prophylaxis and/...
|
|
WO/2024/097736A1 |
Disclosed are processes for preparing azolopyrimidine compounds (including etrumadenant), process intermediates useful for the preparation of azolopyrimidine compounds, and pharmaceutical compositions comprising the same. A particularly ...
|
|
WO/2024/096753A1 |
The present invention provides compounds of Formula (la) or (lb): and methods of use thereof.
|
|
WO/2024/095053A1 |
The present invention relates to a novel non-oral formulation of factor Xa inhibitors comprising factor Xa inhibitor and pharmaceutically acceptable excipients selected from vehicles, surface active agents, co-solvents and stabilizers. T...
|
|
WO/2024/094190A1 |
The present invention relates to use of compounds of formula I and formula II, and specifically relates to use of compound A1-A52, B1-B5, or C1-C36 in the preparation of a drug for treating and/or preventing an inflammatory or immune dis...
|
|
WO/2024/093412A1 |
A heterocyclic compound, a preparation method therefor, and an application thereof. The structural formula of the heterocyclic compound is as represented by formula I. The present compound has excellent bioavailability, can improve cereb...
|
|
WO/2024/094816A1 |
The invention provides a compound of formula (I), or a pharmaceutically acceptable salt, ester or carbamate thereof, or a salt of such an ester or carbamate, wherein either: R1 is OH, and R2 is H; or R1 is H, and R2 is OH. The invention ...
|
|
WO/2024/095003A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: Formula (I) wherein Z, X, R1, R2, R4, R5, R6 and R7 are as defined in the specification, processes fo...
|
